Reumatología

2012

1. 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

   Arthritis Care and Research, Vol. 64, Núm. 10, pp. 1431-1446

2. 2012 American college of rheumatology guidelines for management of gout. part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

   Arthritis Care and Research, Vol. 64, Núm. 10, pp. 1447-1461

3. Análisis del polimorfismo rs20541 (R130Q) del gen de la IL-13 en pacientes con enfermedades inflamatorias crónicas asociadas al envejecimiento

   Reumatologia Clinica, Vol. 8, Núm. 6, pp. 321-327

4. Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010

   The Lancet, Vol. 380, Núm. 9859, pp. 2129-2143

5. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study

   Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1861-1864

6. Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol

   Pain Practice, Vol. 12, Núm. 4, pp. 290-306

7. Developing a provisional definition of flare in patients with established gout

   Arthritis and Rheumatism, Vol. 64, Núm. 5, pp. 1508-1517

8. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

   The Lancet, Vol. 380, Núm. 9859, pp. 2197-2223

9. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: Results of an open-label, phase 3b study

   Journal of Pain Research, Vol. 5, pp. 121-138

10. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial

    Journal of Rheumatology, Vol. 39, Núm. 9, pp. 1859-1866

11. Evaluation and treatment of gout as a chronic disease

    Advances in Therapy, Vol. 29, Núm. 11, pp. 935-946

12. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2095-2128

13. Gout: Why is this curable disease so seldom cured?

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1765-1770

14. Manifestaciones otorrinolaringológicas en pacientes con granulomatosis de Wegener (granulomatosis con poliangeitis)

    Acta Otorrinolaringologica Espanola, Vol. 63, Núm. 3, pp. 206-211

15. Utilizing registries in systemic lupus erythematosus clinical research

    Expert Review of Clinical Immunology, Vol. 8, Núm. 4, pp. 353-360

16. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010

    The Lancet, Vol. 380, Núm. 9859, pp. 2163-2196